Stay updated on Pembrolizumab First-line in Advanced Merkel Cell Carcinoma Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab First-line in Advanced Merkel Cell Carcinoma Clinical Trial page.

Latest updates to the Pembrolizumab First-line in Advanced Merkel Cell Carcinoma Clinical Trial page
- CheckyesterdayChange DetectedThe page now includes a notice about heavy traffic affecting the performance and availability of some NLM-NCBI services and products, along with a contact email for assistance.SummaryDifference1%
- Check8 days agoChange DetectedThe website has been updated from version 2.14.1 to 2.14.2.SummaryDifference0.1%
- Check15 days agoNo Change Detected
- Check22 days agoChange DetectedThe website has been updated from version 2.14.0 to 2.14.1.SummaryDifference0.1%
- Check30 days agoChange DetectedThe website has updated the 'type of intervention' feature from version 2.13.3 to 2.14.0, indicating a significant change in this functionality.SummaryDifference0.2%
- Check37 days agoChange DetectedThe latest update includes detailed definitions and assessments of Duration of Response (DOR), Progression-Free Survival (PFS), and Overall Survival (OS) for participants in the MK-3475-913 study, with a notable increase in the DOR reporting period from approximately 13 years to 58 months, while previous entries have been removed.SummaryDifference3%
- Check59 days agoChange DetectedThe website has been updated from version 2.13.2 to 2.13.3.SummaryDifference0.1%
Stay in the know with updates to Pembrolizumab First-line in Advanced Merkel Cell Carcinoma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab First-line in Advanced Merkel Cell Carcinoma Clinical Trial page.